FRONTIER
CANCER CENTER
AND BLOOD INSTITUTE

1315 Golden Valley Circle
Billings, Montana 59102

February 16, 2011

RECEIVED

FEB 16 2011

DNMS

Mr. Roberto J. Torres
U.S. Nuclear Regulatory Commission
612 East Lamar Boulevard, Suite 400
Arlington, Texas 76011-4125

Dear Mr. Torres,

Please amend our NRC License 25-29392-01 (Frontier Cancer Centers and Blood Institute) to name Dr. Wolfram Laub as the RSO listed on our license.

Thank you,

Mary Beery
Chief Operating Officer
Frontier Cancer Center
406-238-6901
mbeery@frontiercancer.com

ML110470235

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES

RADIOACTIVE MATERIALS LICENSE

License No. ORE-91060
Amendment Number 5

Pursuant to the Radiation Control Act and the Oregon Rules for the Control of Radiation, and in reliance on statements and representations heretofore made by the Licensee designated below, a license is hereby issued authorizing such licensee to transfer, receive, possess and use the radioactive material(s) designated below; and to use such radioactive materials for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations, and orders now or hereafter in effect of the State Health Division and to any and all conditions specified below.

In accordance with letter and facsimile document dated September 17, 2008 and email correspondence dated September 24, 2008, Oregon Radioactive Materials License ORE-91060 is amended to read as follows:

Licensee		3. License Number
1. Name	Pacific Oncology	ORE-91060
		4. Expiration Date: November 30, 2011
2. Address	15700 SW Greystone Ct. Beaverton, OR 97006	5. Reference Number: P.E.T. Imaging/No QMP

	6. Radioactive materials (element and mass number)		7. Chemical and/or physical form		8. Maximum quantity licensee may possess at any one time
A.	Fluorine-18	A.	Fluoro-2-deoxy-D-glucose	A.	As needed.
B.	Sodium-22	B.	Sealed source (Isotope Products Laboratories Model GF-0227)	B.	One source not to exceed 3.7 MBq (100 microcuries).
C.	Sodium-22	C.	Sealed source (Isotope Products Laboratories Model MMS05-22-10U)	C.	Six sources not to exceed 0.37 MBq (10 microcuries) each.

9. Authorized use:

   A. Medical use permitted under OAR 333-116-320 for Positron Emission Tomography (P.E.T.) Imaging and Localization under contract with EPIC Imaging.

   B. and C. For calibration of Philips Medical Systems GXL PET/CT detector scanner.

CONDITIONS

10. Radioactive materials listed in Items 6, 7, and 8 above shall only be used 15700 SW Greystone Court, Beaverton, Oregon 97006.

11. This license is subject to and void without an annual validation certificate. Insofar as the licensee has submitted the proper fee prior to the expiration of a validation certificate, such existing validation certificate shall not expire until the issuance of a new validation certificate for the then current fiscal year.

12. The Radiation Safety Officer for the activities authorized by this license is Wolfram Laub, Ph.D., DABR.

RECEIVED
FEB 16 2011
DNMS

Continued from Page 1

RADIOACTIVE MATERIALS LICENSE

CONDITIONS (cont.)

13. A. Licensed radioactive material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

NAME	USE
Gerald L. Warnock, M.D.	Subitems A, B and C
Ryan Lee Taylor, M.D.	Subitems A, B and C
Daniel Robert Kocarnik, M.D.	Subitems A, B and C
Christopher James Altenhofen, M.D.	Subitems A, B and C
Jennifer P. Mayberry, M.D.	Subitems A, B and C
Warren S. Tubbs, M.D.	Subitems A, B and C
Tyler B. Lippincott, M.D.	Subitem C
Jay A. Bocchi, M.D.	Subitem C

B. The Medical Physicist for this license is Wolfram Laub, Ph.D., DABR.

14. The licensee is authorized to receive, possess and use as reference and calibration sources:

A. Sealed sources of radioactive material containing cobalt-57 not to exceed 20 millicuries.

B. Sealed sources of radioactive material with a half-life longer than 100 days in individual amounts not to exceed 1 millicurie.

C. Technetium-99m in individual amounts not to exceed 100 millicuries.

15. Insofar as the licensee restricts the possession of unsealed byproduct material or readily dispensable source to quantities less than 10^4 or 10^5 of the applicable limits in Appendix B of 10 CFR Part 30, as specified in 10 CFR 30.35(d), or 40.36(b), or 70.25(d), the licensee is not required to provide financial assurance pursuant to OAR 333-102-0200(6).

16. **The clinical trial, *A Radomized Phase 2 Study of SCH 727965 in Subjects with Advanced Breast and Non-Small Cell Lung Cancers*, shall be conducted in accordance with statements, representations and procedures in facsimile document and letter dated September 17, 2008, Protocol No. P04716, WIRB Protocol # 20080184, and Clinical Trials Identifier NCT00732810. A report shall be made to the licensee's IRB with a copy to DHS Public Health Division, Radiation Protection Services on or before June 30, 2009.**

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations and procedures contained in the documents, including any enclosures listed below, except for minor changes in medical use radiation safety procedures as provided in OAR 333-116-0370. The Oregon Rules for the Control of Radiation shall govern, unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the rules.

Continued from Page 2

CONDITIONS (cont.)

(17.) A. Unsigned application and supporting documents submitted November 8, 2006, by Brock Price.

B. Application dated November 10, 2006, signed by Cindy J. Daoust, BSRT (R)(T).

C. Facsimile document dated November 14, 2006, from Brock Price.

D. Email correspondence dated November 14, 2006, from Brock Price.

E. Email correspondence dated November 20, 2006, from Brock Price.

F. Email correspondence dated December 2, 2006, from Brock Price.

G. Letter dated December 11, 2006, signed by Cindy J. Daoust, BSRT (R)(T).

H. Email correspondence dated December 21, 2006, from Brock Price.

I. Email correspondence dated August 17, 2007, from Wolfram Laub, Ph.D., DABR.

J. Email correspondence dated December 4, 2007, from Wolfram Laub.

K. Letter and facsimile document dated September 17, 2008, signed by Yolanda Prado, Clinical Research Coordinator.

L. Email correspondence dated September 24, 2008, from Yolanda Prado, CCRP, Clinical Research Coordinator.

Date: September 26, 2008

FOR DHS PUBLIC HEALTH DIVISION

By _____
Todd S. Carpenter, Manager
Radioactive Materials Licensing Program

Torres, RobertoJ

From: Mary Beery [mbeery@frontiercancer.com]
Sent: Wednesday, February 16, 2011 9:59 AM
To: Torres, RobertoJ
Cc: Wolfram Laub; Wolfram Laub
Subject: Mail Control # 574117
Attachments: 574117.pdf

Mr. Torres,
Attached is a letter asking that the RSO be changed on NRC license 25-29392-01 for Frontier Cancer Centers and Blood Institute to Dr. Wolfram Laub. I have also attached a copy of the Oregon license 91060 which names Dr. Laub as the RSO.

Thank you,

Mary Beery
Chief Operating Officer
Frontier Cancer Center
406-238-6901

Torres, RobertoJ

From: Torres, RobertoJ
Sent: Monday, February 14, 2011 7:36 AM
To: 'laubw@ohsu.edu'
Subject: Request for additional information

Dr. Laub:

The NRC Region IV has received your amendment request to name you RSO on NRC License 25-29392-01 (Frontier Cancer Centers and Blood Institute). Please note that this amendment has to be requested by a manager from Frontier Cancer Centers or by the RSO listed on the license. When Frontier re-submits the amendment request please include copy of Oregon license 91060 naming you RSO (this will help expedite the amendment process).

The resubmission (signed/dated letter from Frontier) can be made by reply email as a pdf file or by fax to 817-860-8263. Please make reference to mail control number 574117 and send to my attention. Please resubmit within 14 working days. Thank you.

Thank you.

Roberto J. Torres
Senior Health Physicist
U.S. Nuclear Regulatory Commission - Region IV
Division of Nuclear Materials Safety
Nuclear Materials Safety Branch B
612 East Lamar Boulevard, Suite 400
Arlington, Texas 76011-4125
Telephone 817-860-8189
Facsimile 817-860-8263
robertoj.torres@nrc.gov

Torres, RobertoJ

From: Torres, RobertoJ
Sent: Tuesday, February 08, 2011 3:51 PM
To: 'Wolfram.laub@pacificoncology.org' → undeliverable
Subject: Request for additional information

Dr. Laub:

The NRC Region IV has received your amendment request to name you RSO on NRC License 25-29392-01 (Frontier Cancer Centers and Blood Institute). Please note that this amendment has to be requested by a manager from Frontier Cancer Centers or by the RSO listed on the license. When Frontier re-submits the amendment request please include copy of Oregon license 91060 naming you RSO (this will help expedite the amendment process).

The resubmission (signed/dated letter from Frontier) can be made by reply email as a pdf file or by fax to 817-860-8263. Please make reference to mail control number 574117 and send to my attention. Please resubmit within 14 working days. Thank you.

Thank you.

Roberto J. Torres
Senior Health Physicist
U.S. Nuclear Regulatory Commission - Region IV
Division of Nuclear Materials Safety
Nuclear Materials Safety Branch B
612 East Lamar Boulevard, Suite 400
Arlington, Texas 76011-4125
Telephone 817-860-8189
Facsimile 817-860-8263
robertoj.torres@nrc.gov